2023 was another busy and exciting year for the Pediatric Trials Network (PTN). This year, the Network upheld its commitment to improving pediatric care by changing labels, performing research, connecting with partners, and sharing science. The PTN would like to thank its participants, members, and partners for their continued support in making a difference for children and families worldwide!
This year, the PTN contributed data to two U.S. Food and Drug Administration (FDA) medication label changes. FDA label changes help health care providers prescribe the safest, most effective dosages of medicines to children. These label changes make 19, in total, that the PTN has informed to date. Three PTN studies reached milestones in 2023. Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose Intravenous Methadone in Healthy Adult Volunteers (MTH02) enrolled its first participants; CUDDLE added seven medications to the list of those being studied; and the Safety of Sildenafil in Premature Infants study opened its third and final cohort. Including these, the PTN supported six ongoing studies in 2023, and one new study is expected to begin enrolling in 2024.
Throughout 2023, the PTN connected with its partners at the Pediatric Academic Societies Annual Meeting and the International Children’s Advisory Network (iCAN) Summit. Events at these meetings included a debate between PTN investigators and informational sessions on the work of PTN and iCAN.
Since last year’s report, the PTN has released four new publications and three new results-at-a-glance summaries. Additionally, the PTN started sharing its methods for analyzing various biological samples with the scientific community.